Citations

Showing 10 of 108081 citations.

Magnetic and Biocompatible Polyurethane Nanofiber Biomaterial for Tissue Engineering
Dragomir‐Daescu, Dan , Sandhu, Gurpreet S. , Tefft, Brandon J. , Choe, Joshua A. , Uthamaraj, Susheil , Dragomir-Daescu, Dan, Tefft, Brandon J

Mayo Clinic

Tissue Engineering Part A | May 2, 2023 | Volume: 29 | Issue: 15-16 | Pages: 413-423

10.1089/ten.tea.2022.0224 | PMID 37130041 Get It

Recruitment of endothelial cells to cardiovascular device surfaces could solve issues of thrombosis, neointimal hyperplasia, and restenosis. Since current targeting strategies are often nonspecific, new technologies to allow for site-specific cell localization and capture in vivo are needed. The development of cytocompatible superparamagnetic iron oxide nanoparticles has allowed for the use of magnetism for cell targeting. In this study, a magnetic polyurethane (PU)-2205 stainless steel (2205-SS) nanofibrous composite biomaterial was developed through analysis of composite sheets and application to stent-grafts. The PU nanofibers provide strength and elasticity while the 2205-SS microparticles provide ferromagnetic properties. Sheets were electrospun at mass ratios of 0–4:1 (2205-SS:PU) and stent-grafts with magnetic or nonmagnetic stents were coated at the optimal ratio of 2:1. These composite materials were characterized by microscopy, mechanical testing, a sessile drop test, magnetic field measurement, magnetic cell capture assays, and cytocompatibility after 14 days of culturing with endothelial cells. Results of this study show that an optimal ratio of 2:1 2205-SS:PU results in a hydrophobic material that balanced mechanical and magnetic properties and was cytocompatible up to 14 days. Significant cell capture required a thicker material of 0.5 mm thickness. Stent-grafts fabricated from a magnetic coating and a magnetic stent demonstrated uniform cell capture throughout the device surface. This novel biomaterial exhibits a combination of mechanical and magnetic properties that enables magnetic capture of cells and other therapeutic agents for vascular and other tissue engineering applications.
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Joyner, Michael J. , Senefeld, Jonathon W. , Focosi, Daniele , Casadevall, Arturo , Focosi, Daniele , Joyner, Michael J , Senefeld, Jonathon W , Casadevall, Arturo , Pirofski, Liise‐anne , Shoham, Shmuel , Sullivan, David , Paneth, Nigel

Mayo Clinic

Expert Review of Respiratory Medicine | May 2, 2023 | Volume: 17 | Issue: 5 | Pages: 381-395

10.1080/17476348.2023.2208349 | PMID 37129285 Get It

Randomised trial of stable chest pain investigation: 3-year clinical and quality of life results from CE-MARC 2
Everett, Colin , McCann, Gerry P , Fernandez, Catherine , Reynolds, Catherine, Bucciarelli‐Ducci, Chiara , Dall’Armellina, Erica , Foley, James RJ, Brown, Julia , Stocken, Deborah , Plein, Sven , Greenwood, John P. , McCann, Gerry P , Walker, Simon , Greenwood, John P , Bucciarelli-Ducci, Chiara , Plein, Sven , Berry, Colin , Prasad, Abhiram , Mangion, Kenneth , Bijsterveld, Petra , Walker, Simon , Sculpher, Mark

Mayo Clinic

Open Heart | May 2, 2023 | Volume: 10 | Issue: 1 | Pages: e002221

10.1136/openhrt-2022-002221 | PMID 37130657 Get It

Aims Guidelines for suspected cardiac chest pain have used historical risk stratification tools, advocating invasive coronary angiography (ICA) first-line in those at highest risk. We aimed to determine whether different strategies to manage suspected stable angina affected medium-term cardiovascular event rates and patient-reported quality of life (QoL) measures. Methods CE-MARC 2, a three-arm parallel group trial, randomised patients with suspected stable cardiac chest pain and a Duke Clinical pretest likelihood of coronary artery disease between 10% and 90%. Patients were randomised to either first-line cardiovascular magnetic resonance (CMR), single-photon emission computed tomography (SPECT) or the UK National Institute for Health and Care Excellence (NICE) CG95 (2010) guidelines-directed care. For the three arms, 1-year and 3-year first major adverse cardiovascular event (MACE) rates and QoL assessed by the Seattle Angina Questionnaire, Short Form 12 (V.12) Questionnaire and EuroQol-5 Dimension Questionnaire were recorded. Results 1202 patients were randomised to CMR (n=481), SPECT (n=481) and NICE (n=240). Forty-two patients (18 CMR, 18 SPECT, 6 NICE) experienced one or more MACEs. The percentage rates (95% CIs) of MACE in the CMR, SPECT and NICE groups at 3 years were 3.7% (2.4%, 5.8%), 3.7% (2.4%, 5.8%) and 2.1% (0.9%, 4.8%), respectively. QoL scores did not significantly differ across domains. Conclusion Despite a fourfold increase in referrals for ICA, the NICE CG95 (2010) guidelines risk-stratified care strategy did not significantly reduce 3-year MACE or improve QoL, as compared with functional imaging with CMR or SPECT. Trial registration number ClinicalTrials.gov Registry (NCT01664858).
Gastroparesis: an under-recognised manifestation of systemic amyloidosis
Abdullah, Khaled, Alsuraimi, Anas , Kagbo-Kue, Suaka , Vela, Marcelo F. , Vela, Marcelo

Mayo Clinic

BMJ Case Reports | May 2, 2023 | Volume: 16 | Issue: 5 | Pages: e254634

10.1136/bcr-2023-254634 | PMID 37130641 Get It

Gastrointestinal (GI) amyloidosis can be acquired or genetic and is commonly caused by chronic inflammatory illnesses (AA amyloidosis), haematological malignancies (AL amyloidosis) and end-stage renal disease (beta-2 microglobulin amyloidosis). The accumulation of these aberrant proteins disrupts the structures and functions of many organs; the least common of which is the GI tract. GI presentations depend on the type, location and amount of amyloid deposition. Symptoms can range from nausea and vomiting to fatal GI bleeds. Pathological examination of the involved tissue with characteristic green birefringence under polarised light is used to confirm the diagnosis. Patients should be considered for further evaluation to rule out additional organ involvement, notably cardiac and renal. We present a patient with amyloidosis-induced gastroparesis, an under-recognised presentation of systemic amyloidosis in the gastroenterology system.
National Trends in Mental Health–Related Emergency Department Visits Among Youth, 2011-2020
Bommersbach, Tanner J. , McKean, Alastair J. , Rhee, Taeho Greg , Olfson, Mark

Mayo Clinic

JAMA | May 2, 2023 | Volume: 329 | Issue: 17 | Pages: 1469

10.1001/jama.2023.4809 | PMID 37129655 Get It

Importance There has been increasing concern about the burden of mental health problems among youth, especially since the COVID-19 pandemic. Trends in mental health–related emergency department (ED) visits are an important indicator of unmet outpatient mental health needs. Objective To estimate annual trends in mental health–related ED visits among US children, adolescents, and young adults between 2011 and 2020. Design, Setting, and Participants Data from 2011 to 2020 in the National Hospital Ambulatory Medical Care Survey, an annual cross-sectional national probability sample survey of EDs, was used to examine mental health–related visits for youths aged 6 to 24 years (unweighted = 49 515). Main Outcomes and Measures Mental health–related ED visits included visits associated with psychiatric or substance use disorders and were identified by International Classification of Diseases-Ninth Revision, Clinical Modification ( ICD-9-CM ; 2011-2015) and ICD-10-CM (2016-2020) discharge diagnosis codes or by reason-for-visit (RFV) codes. We estimated the annual proportion of mental health–related pediatric ED visits from 2011 to 2020. Subgroup analyses were performed by demographics and broad psychiatric diagnoses. Multivariable-adjusted logistic regression analyses estimated factors independently associated with mental health–related ED visits controlling for period effects. Results From 2011 to 2020, the weighted number of pediatric mental health–related visits increased from 4.8 million (7.7% of all pediatric ED visits) to 7.5 million (13.1% of all ED visits) with an average annual percent change of 8.0% (95% CI, 6.1%-10.1%; P < .001). Significant linearly increasing trends were seen among children, adolescents, and young adults, with the greatest increase among adolescents and across sex and race and ethnicity. While all types of mental health–related visits significantly increased, suicide-related visits demonstrated the greatest increase from 0.9% to 4.2% of all pediatric ED visits (average annual percent change, 23.1% [95% CI, 19.0%-27.5%]; P < .001). Conclusions and Relevance Over the last 10 years, the proportion of pediatric ED visits for mental health reasons has approximately doubled, including a 5-fold increase in suicide-related visits. These findings underscore an urgent need to improve crisis and emergency mental health service capacity for young people, especially for children experiencing suicidal symptoms.
Image-guided Bronchoscopy: Established and Emerging Approaches
Swenson, Kai E. , DuComb, Emily A. , Parikh, Mihir , Abia‐Trujillo, David , Majid, Adnan

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 2, 2023 | Volume: 208 | Issue: 1 | Pages: 98-100

10.1164/rccm.202205-1008rr | PMID 37129567 Get It

Dual TCR-Expressing T Cells in Cancer: How Single-Cell Technologies Enable New Investigation
Muhowski, Elizabeth M. , Rogers, Laura M. , Rogers, Laura M

Mayo Clinic

ImmunoHorizons | May 2, 2023 | Volume: 7 | Issue: 5 | Pages: 299-306

10.4049/immunohorizons.2200062 | PMID 37129560 Get It

Abstract TCR diversity measures are often used to understand the immune response in cancer. Traditional measures of diversity rely on bulk RNA sequencing (RNAseq) of the β-chain variable regions. However, the full αβ TCR repertoire is a combination of both the α- and β-chains, which are encoded by separate genes. In contrast with bulk RNAseq, single-cell RNAseq (scRNAseq) allows paired chain analyses, yielding a more accurate measure of the repertoire. Interestingly, ∼30% of mature peripheral T cells express multiple TCR alleles (e.g., two α-chains) and may exhibit dual Ag specificity. scRNAseq has become increasingly common, and data from both human and animal studies are publicly available. However, routine workflows discard secondary TCR alleles and focus on a single TCR clone per cell. This perspectives piece emphasizes why this may not be good practice and highlights unanswered questions in the field of T cell dual specificity.
Cardiovascular benefits and risks associated with calcium, vitamin D, and antiresorptive therapy in the management of skeletal fragility
Kittithaworn, Annop , Toro-Tobón, David , Sfeir, Jad , Sfeir, Jad G , Toro-Tobon, David

Mayo Clinic

Women's Health | May 2, 2023 | Volume: 19 | Issue: No issue available | Pages: No page available

10.1177/17455057231170059 | PMID 37129172 Get It

Osteoporosis affects one in every five women over the age of 50 worldwide. With a rapidly ageing population, the prevalence of fragility fractures, considered a largely preventable consequence of osteoporosis, is expected to increase. Age is also a major risk for cardiovascular disease and mortality, thus highlighting the importance of cardiovascular profiling of osteoporosis interventions. Although calcium and vitamin D are essential for a healthy bone metabolism, excessive supplementation may be associated with increased risk. Conversely, early pre-clinical data have suggested a possible cardiovascular benefit from bisphosphonate therapy. This review evaluates the evidence behind the cardiovascular benefits and risks that may be associated with osteoporosis therapy.
Mucosal Architectural Change is an Important Feature in Distinguishing Crohn's Disease From Others in Terminal Ileum Ulcer Biopsy
Zhong, Tingting , Zhang, Lizhi , Wu, Yanchuang, Pan, Yipeng, Xu, Jiaqi , Cao, Qian , Jiang, Zhinong , Jiang, Zhinong , Tang, Wen , Fu, Yujuan

Mayo Clinic

International Journal of Surgical Pathology | May 2, 2023 | Volume: 32 | Issue: 1 | Pages: 75-82

10.1177/10668969231171135 | PMID 37128682 Get It

Background Besides Crohn's disease (CD), there are a variety of other causes that can also lead to ulcerations in the terminal ileum. The purpose of this study was to identify useful diagnostic features for CD when evaluating terminal ileum biopsies in patients with endoscopic finding of ulcers. Methods Five hundred and seventy-one patients with endoscopic finding of ulcers were included in this retrospective study. Five main histological features were analysed, which were crypt irregularity, mucosal thickening, villous stromal widening (including villous atrophy), granulomas, and pseudopyloric gland metaplasia. Clinical and pathological features were determined by uni- and multivariable logistic regression. Then another independent cohort of 99 patients was established for verifying this nomogram. Results The crypt irregularity, mucosal thickening, and villous stromal widening were combined to be considered as one new variable named mucosal architectural change which was an independent variable in diagnosing CD. We found that mucosal architectural change, age <40 years, the presence of granulomas, and the presence of pseudopyloric gland metaplasia were independent factors for the pathological diagnosis of CD. Then nomogram was developed, with receiver operating characteristic (ROC) curve (area under the ROC curve [AUC] = 0.927) in training sets, and ROC curve (AUC = 0.913) in validation sets. Conclusions We found mucosal architectural change is very helpful in distinguishing CD from non-CD patients. In the context of small biopsy which may lack full scope of changes, the model developed by combining these key features is valuable in predicting a diagnosis of CD, especially in younger patients (age <40 years).
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Harrison, Claire , Nangalia, Jyoti , Boucher, Rebecca H. , Jackson, Aimee , Yap, Christina , O’Sullivan, Jennifer , Fox, Sonia, Ailts, Isaak , Dueck, Amylou C. , Geyer, Holly L. , Nadezhdin, Eugene, Curto‐García, Natalia , Green, Anna , Wilkins, Bridget S., Coppell, Jason, Laurie, John , Garg, Mamta , Ewing, Joanne, Knapper, Steven , Crowe, Josephine , Koutsavlis, Ioannis , Godfrey, Anna L. , Arami, Siamak , Drummond, Mark W., Clark, Fiona , Mead‐Harvey, Carolyn , Baxter, E. Joanna , Mead, Adam J. , Dueck, A. C. , Harrison, Claire N , Boucher, Rebecca , Mesa, Ruben , Dunn, William G , Garg, Mamta , Knapper, Steven , Crowe, Josephine , Koutsavlis, Ioannis , Arami, Siamak , Byrne, Jennifer , Baxter, Elizabeth Joanna , McMullin, Mary Frances , Mead, Adam J , Yap, Christina , Mesa, Ruben A. , Dunn, William G. , Chen, Frederick , Byrne, Jenny , McMullin, Mary Frances

Mayo Clinic

Journal of Clinical Oncology | May 1, 2023 | Volume: 41 | Issue: 19 | Pages: 3534-3544

10.1200/jco.22.01935 | PMID 37126762 Get It

PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. PATIENTS AND METHODS MAJIC-PV is a randomized phase II trial of ruxolitinib versus best available therapy (BAT) in patients resistant/intolerant to hydroxycarbamide (HC-INT/RES). Primary outcome was complete response (CR) within 1 year. Secondary outcomes included duration of response, event-free survival (EFS), symptom, and molecular response. RESULTS One hundred eighty patients were randomly assigned. CR was achieved in 40 (43%) patients on ruxolitinib versus 23 (26%) on BAT (odds ratio, 2.12; 90% CI, 1.25 to 3.60; P = .02). Duration of CR was superior for ruxolitinib (hazard ratio [HR], 0.38; 95% CI, 0.24 to 0.61; P < .001). Symptom responses were better with ruxolitinib and durable. EFS (major thrombosis, hemorrhage, transformation, and death) was superior for patients attaining CR within 1 year (HR, 0.41; 95% CI, 0.21 to 0.78; P = .01); and those on ruxolitinib (HR, 0.58; 95% CI, 0.35 to 0.94; P = .03). Serial analysis of JAK2V617F variant allele fraction revealed molecular response was more frequent with ruxolitinib and was associated with improved outcomes (progression-free survival [PFS] P = .001, EFS P = .001, overall survival P = .01) and clearance of JAK2V617F stem/progenitor cells. ASXL1 mutations predicted for adverse EFS (HR, 3.02; 95% CI, 1.47 to 6.17; P = .003). The safety profile of ruxolitinib was as previously reported. CONCLUSION The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.